Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases. It utilizes a macrocycle platform for its pipeline of compact tyrosine kinase inhibitors. The company develops Repotrectinib, a drug candidate for the treatment of patients with advanced solid tumors.